Silk Road Medical Inc (SILK)
29.42
+0.58 (+2.01%)
USD |
NASDAQ |
May 23, 16:00
29.39
-0.03 (-0.10%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.033B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -37.60% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 9.531 |
| Price to Book Value | 15.26 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7197 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
05/17 09:08
MT Newswires
05/04 16:37
MT Newswires
05/02 10:23
Globe Newswire
05/02 08:30
Globe Newswire
04/26 16:10
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 07/29/2022* | -- | Results | Q2 2022 | -- | -0.45 | -- | |
| 07/29/2022* | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -0.48 | -0.37 | -28.86% | |
| 05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/24/2022 | -- | Results | Q4 2021 | -0.42 | -0.33 | -26.00% | |
| 02/24/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.40 | -0.28 | -42.86% | |
| 11/09/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk. |
| URL | https://www.silkroadmed.com |
| Investor Relations URL | https://investors.silkroadmed.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 23, 2022.
Fundamentals
| Revenue (TTM) | 107.44M |
| Total Expenses (TTM) | 160.70M |
| Net Income (TTM) | -55.80M |
| Total Assets (Quarterly) | 143.00M |
| Total Liabilities (Quarterly) | 75.29M |
| Shareholders Equity (Quarterly) | 67.71M |
| Cash from Operations (TTM) | -41.69M |
| Cash from Investing (TTM) | 34.34M |
| Cash from Financing (TTM) | 6.298M |
Ratings
Profile
Edit
| Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of innovative endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk. |
| URL | https://www.silkroadmed.com |
| Investor Relations URL | https://investors.silkroadmed.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | May. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SILK Tweets |